Daniel Roth, MD
Retina Specialist · New Brunswick, NJNPI 1538132352
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,490 of the $61,139 with a category attached, or 67.9%. Astellas Pharma US Inc accounts for 78.7% of it on its own, with 10 other manufacturers making up the rest.
Across 131 payments — averaging $466.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$48K
- Alimera Sciences, Inc.$6K
- Apellis Pharmaceuticals, Inc.$4K
- Novartis$2K
- Regeneron Healthcare Solutions, Inc.$399
- Eyepoint US, Inc.$285
- plus $354 from 5 others
Across 117 payments — averaging $2563.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$215K
- Eyepoint US, Inc.$40K
- Astellas Pharma Global Development$30K
- Regeneron$13K
- Notal Vision, Inc.$1K
What the payments were for
- Consulting fees$14,83024%
- Speaking & faculty fees$41,49068%
- Travel & lodging$1,9973%
- Food & beverage$2,8225%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 46 | $48,123 |
| Alimera Sciences, Inc. | 7 | $5,916 |
| Apellis Pharmaceuticals, Inc. | 36 | $4,012 |
| Novartis | 1 | $2,050 |
| Regeneron Healthcare Solutions, Inc. | 23 | $399 |
| Eyepoint US, Inc. | 4 | $285 |
| AbbVie | 7 | $112 |
| Genentech USA, Inc. | 3 | $111 |
| Regeneron | 1 | $90 |
| Bausch & Lomb Americas Inc. | 2 | $27 |
| Sandoz | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,139 in reported general payments places this provider in the 85th percentile of 35 retina specialist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 140 | $7,101 |
| LumiganBimatoprost | 18 | $7,023 |
| Brimonidine Tartrate | 34 | $3,609 |
| Latanoprost | 181 | $1,877 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 88 | $1,479 |
| Travoprost | 14 | $1,240 |
| Atropine Sulfate | 28 | $831 |
| Ketorolac Tromethamine | 15 | $613 |
| Timolol Maleate | 43 | $425 |
| MoxifloxacinMoxifloxacin Hcl | 16 | $331 |
| Dorzolamide Hcl | 12 | $271 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 34 | $206 |
| Cyclopentolate Hcl | 12 | $181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $112 | $7,02318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 35 retina specialist providers in New Jersey.
Other retina specialist in New Brunswick
- Howard FineNew Brunswick$955K
- Jonathan PrennerNew Brunswick$215K
- Sumit ShahNew Brunswick$41K
- Harold WheatleyNew Brunswick$13K
- Bruce KeyserNew Brunswick$8K
- Eric FriedmanNew Brunswick$554
- Stuart GreenNew Brunswick$22
- Joshua MaliFlemington$230K
- Leonard FeinerUnion$72K
- Vatsal DoshiMillburn$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.